Andrew Moreno

DocwireNews

A team of clinical experts has analyzed data from the international phase 2 REVIVE trial, which investigated control of erythrocytosis in phlebotomy-dependent polycythemia vera using rusfertide, an injectable hepcidin mimetic. The team&rsquo;s efficacy and safety findings were published in The New England Journal of Medicine.&ldquo;Rusfertide is a potentially effective treatment option for achieving and sustaining hematocrit control in patients with polycythemia vera, reducing the use of phlebotomy and the occurrence of debilitating disease-related symptoms,&rdquo; wrote first author Marina Kremyanskaya, MD, PhD, of Icahn School of Medicine at Mount Sinai, New York, and colleagues.Part 1 of the trial was a 28-week dose-finding assessment of rusfertide, which involved 70 patients with polycythemia vera. Fifty-nine of these patients were included in part 2 of the trial, a 12-week, double-blind, randomized withdrawal period during which 30 patients received rusfertide and 29 received placebo.Regarding hematocrit control as a measure of rusfertide&rsquo;s efficacy, the average maximum hematocrit among the patients was 50.0% during the 28 weeks before the first dose of rusfertide and fell to 44.5% during part 1. Regarding the number of phlebotomies per year, the estimated average number was 8.7 during the 28 weeks before the first rusfertide dose and fell to 0.6 during part 1.&ldquo;Between baseline and the end of part 1, rusfertide treatment was associated with a decrease in individual symptom scores on the MPN-SAF [modified Myeloproliferative Neoplasm Symptom Assessment Form] in patients with moderate or severe symptoms at baseline,&rdquo; Kremyanskaya and colleagues mentioned.During part 2, the investigators observed that 60% of the patients who received rusfertide responded, compared with 17% of the patients who received placebo (P=0.002).Regarding adverse events in parts 1 and 2, injection-site reactions of grade 1 or 2 severity were prevalent. Grade 3 adverse events affected 13% of the patients, and there were no grade 4 or 5 events.Study coauthor Andrew Kuykendall, MD, of Moffitt Cancer Center, Tampa, Florida, in comments forwarded to Heme Today, conveyed his view that the REVIVE study &ldquo;showed that there may be a preferred alternative to phlebotomy and hematocrit control in general in managing patients with polycythemia vera. The hepcidin mimetic, rusfertide, can effectively eliminate patients&rsquo; needs for phlebotomy and maintain consistent hematocrit control via a well-tolerated once weekly subcutaneous injection. The unique trial design that called for half of patients to be taken off of rusfertide and treated with placebo after 28 weeks provided a glimpse into the comparative benefit of rusfertide. Though brief, this period of comparison showed rapid loss of hematocrit control in patients who did not remain on rusfertide and showed that patients who remained on rusfertide had better control of disease-related symptoms that have long been difficult to manage. Ultimately, these findings led to the ongoing phase 3 VERIFY study which recently reported positive results.&rdquo;Dr. Kremyanskaya also explained, in remarks forwarded to Heme Today, that &ldquo;[w]hat is especially exciting about the REVIVE study is that it utilized a completely novel approach as a potential treatment for polycythemia vera. It used a peptide hormone that is normally made by the liver to regulate iron homeostasis, to restrict iron availability for erythropoiesis, and thus controlled the hematocrit in patients with polycythemia vera. This phase 2 study showed in randomized fashion that this approach utilizing hepcidin mimetic rusfertide significantly decreased the need for therapeutic phlebotomies compared to placebo. It also indicated potential improvement in polycythemia vera related symptoms. Phase 3 VERIFY study is currently ongoing and is confirming these findings in a larger cohort of patients.&rdquo;The REVIVE trial is funded by Protagonist Therapeutics.ReferenceKremyanskaya M, Kuykendall AT, Pemmaraju N, et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med. 2024;390(8):723-735. doi:10.1056/NEJMoa2308809

Mini Michael, MD

Joel M. Topf, MD, FACP

Lumasiran for PH1 in Infants and Young Children

NKF Spring Clinical Meetings 2025

Jordana Jampel

Patent Forman Ovale Status Linked to Cryptogenic Ischemic Stroke Risk Profile for Younger Adults

Neurology

Brandon Twyford

PALMIRA Trial Shows No Significant PFS Benefit From Palbociclib Rechallenge in HR+/HER2- Advanced Breast Cancer

HR Breast Cancer

Latest News

Injectable Rusfertide Shows Promise for Erythrocytosis Control in Phlebotomy-Dependent PV

Polycythemia Vera

The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe